Modulation of JAK-STAT Signaling by LNK: A Forgotten Oncogenic Pathway in Hormone Receptor-Positive Breast Cancer
Open Access
- 30 September 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14777
Abstract
Breast cancer remains the most frequently diagnosed cancer in women worldwide. Tumors that express hormone receptors account for 75% of all cases. Understanding alternative signaling cascades is important for finding new therapeutic targets for hormone receptor-positive breast cancer patients. JAK-STAT signaling is commonly activated in hormone receptor-positive breast tumors, inducing inflammation, proliferation, migration, and treatment resistance in cancer cells. In hormone receptor-positive breast cancer, the JAK-STAT cascade is stimulated by hormones and cytokines, such as prolactin and IL-6. In normal cells, JAK-STAT is inhibited by the action of the adaptor protein, LNK. However, the role of LNK in breast tumors is not fully understood. This review compiles published reports on the expression and activation of the JAK-STAT pathway by IL-6 and prolactin and potential inhibition of the cascade by LNK in hormone receptor-positive breast cancer. Additionally, it includes analyses of available datasets to determine the level of expression of LNK and various members of the JAK-STAT family for the purpose of establishing associations between expression and clinical outcomes. Together, experimental evidence and in silico studies provide a better understanding of the potential implications of the JAK-STAT-LNK loop in hormone receptor-positive breast cancer progression.Keywords
Funding Information
- PAPIIT, UNAM (IN206022)
This publication has 155 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- The landscape of cancer genes and mutational processes in breast cancerNature, 2012
- LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets α‐parvin to control cell adhesion and migrationThe FASEB Journal, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver AgreementJNCI: Journal of the National Cancer Institute, 2011
- Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancerOncogene, 2010
- FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistanceOncogene, 2010
- Signal Transducer and Activator of Transcription 4 Is Required for the Transcription Factor T-bet to Promote T Helper 1 Cell-Fate DeterminationImmunity, 2008
- Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cellsNucleic Acids Research, 2007